These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Xu Y; Liu H; Liu S; Wang Y; Xie J; Stinchcombe TE; Su L; Zhang R; Christiani DC; Li W; Wei Q Int J Cancer; 2018 Nov; 143(10):2400-2408. PubMed ID: 29978465 [TBL] [Abstract][Full Text] [Related]
23. Association of hepsin gene variants with prostate cancer risk and prognosis. Holt SK; Kwon EM; Lin DW; Ostrander EA; Stanford JL Prostate; 2010 Jun; 70(9):1012-9. PubMed ID: 20166135 [TBL] [Abstract][Full Text] [Related]
24. Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families. Karyadi DM; Zhao S; He Q; McIntosh L; Wright JL; Ostrander EA; Feng Z; Stanford JL Int J Cancer; 2015 May; 136(9):2166-71. PubMed ID: 25273821 [TBL] [Abstract][Full Text] [Related]
25. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. Gu F; Zhang H; Hyland PL; Berndt S; Gapstur SM; Wheeler W; Ellipse Consortium T; Amos CI; Bezieau S; Bickeböller H; Brenner H; Brennan P; Chang-Claude J; Conti DV; Doherty JA; Gruber SB; Harrison TA; Hayes RB; Hoffmeister M; Houlston RS; Hung RJ; Jenkins MA; Kraft P; Lawrenson K; McKay J; Markt S; Mucci L; Phelan CM; Qu C; Risch A; Rossing MA; Wichmann HE; Shi J; Schernhammer E; Yu K; Landi MT; Caporaso NE Int J Cancer; 2017 Nov; 141(9):1794-1802. PubMed ID: 28699174 [TBL] [Abstract][Full Text] [Related]
26. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Chen YC; Kraft P; Bretsky P; Ketkar S; Hunter DJ; Albanes D; Altshuler D; Andriole G; Berg CD; Boeing H; Burtt N; Bueno-de-Mesquita B; Cann H; Canzian F; Chanock S; Dunning A; Feigelson HS; Freedman M; Gaziano JM; Giovannucci E; Sánchez MJ; Haiman CA; Hallmans G; Hayes RB; Henderson BE; Hirschhorn J; Kaaks R; Key TJ; Kolonel LN; LeMarchand L; Ma J; Overvad K; Palli D; Pharaoh P; Pike M; Riboli E; Rodriguez C; Setiawan VW; Stampfer M; Stram DO; Thomas G; Thun MJ; Travis RC; Virtamo J; Trichopoulou A; Wacholder S; Weinstein SJ Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1973-81. PubMed ID: 17932344 [TBL] [Abstract][Full Text] [Related]
27. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer. Wu L; Chaffee KG; Parker AS; Sicotte H; Petersen GM Tumour Biol; 2015 Sep; 36(10):7431-7. PubMed ID: 25900876 [TBL] [Abstract][Full Text] [Related]
28. Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. Freedman JA; Wang Y; Li X; Liu H; Moorman PG; George DJ; Lee NH; Hyslop T; Wei Q; Patierno SR Carcinogenesis; 2018 Jul; 39(7):879-888. PubMed ID: 29726910 [TBL] [Abstract][Full Text] [Related]
29. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Langeberg WJ; Kwon EM; Koopmeiners JS; Ostrander EA; Stanford JL Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):258-64. PubMed ID: 20056646 [TBL] [Abstract][Full Text] [Related]
30. Functional variants of RPS6KB1 and PIK3R1 in the autophagy pathway genes and risk of bladder cancer. Ma L; Zhang D; Huang Z; Zheng R; Du M; Lv Q; Qin C; Chu H; Yuan L; Zhang Z Arch Toxicol; 2022 Jan; 96(1):367-375. PubMed ID: 34668023 [TBL] [Abstract][Full Text] [Related]
31. Genetic and functional evidence for a role for SLC11A1 in susceptibility to otitis media in early childhood in a Western Australian population. Rye MS; Wiertsema SP; Scaman ES; Thornton R; Francis RW; Vijayasekaran S; Coates HL; Jamieson SE; Blackwell JM Infect Genet Evol; 2013 Jun; 16():411-8. PubMed ID: 23538334 [TBL] [Abstract][Full Text] [Related]
32. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Juang SH; Bao BY Sci Rep; 2015 Feb; 5():8556. PubMed ID: 25707771 [TBL] [Abstract][Full Text] [Related]
33. Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci. Zhang P; Tillmans LS; Thibodeau SN; Wang L Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31323811 [TBL] [Abstract][Full Text] [Related]
34. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Langeberg WJ; Tahir SA; Feng Z; Kwon EM; Ostrander EA; Thompson TC; Stanford JL Prostate; 2010 Jun; 70(9):1020-35. PubMed ID: 20209490 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Holick CN; Stanford JL; Kwon EM; Ostrander EA; Nejentsev S; Peters U Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1990-9. PubMed ID: 17932346 [TBL] [Abstract][Full Text] [Related]
36. Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy. Langsenlehner T; Thurner EM; Renner W; Gerger A; Kapp KS; Langsenlehner U Strahlenther Onkol; 2014 Apr; 190(4):364-9. PubMed ID: 24435801 [TBL] [Abstract][Full Text] [Related]
37. Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Feng Y; Wang Y; Liu H; Liu Z; Mills C; Owzar K; Xie J; Han Y; Qian DC; Hung Rj RJ; Brhane Y; McLaughlin J; Brennan P; Bickeböller H; Rosenberger A; Houlston RS; Caporaso N; Landi MT; Brüske I; Risch A; Ye Y; Wu X; Christiani DC; Amos CI; Wei Q Mol Carcinog; 2018 Feb; 57(2):216-224. PubMed ID: 29071797 [TBL] [Abstract][Full Text] [Related]
38. Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians. Shan J; Al-Rumaihi K; Rabah D; Al-Bozom I; Kizhakayil D; Farhat K; Al-Said S; Kfoury H; Dsouza SP; Rowe J; Khalak HG; Jafri S; Aigha II; Chouchane L J Transl Med; 2013 May; 11():121. PubMed ID: 23668334 [TBL] [Abstract][Full Text] [Related]
39. Prostate cancer susceptibility variants confer increased risk of disease progression. Cheng I; Plummer SJ; Neslund-Dudas C; Klein EA; Casey G; Rybicki BA; Witte JS Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2124-32. PubMed ID: 20651075 [TBL] [Abstract][Full Text] [Related]
40. Susceptibility loci associated with prostate cancer progression and mortality. Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]